Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial

BJ Slotman; C Faivre-Finn; H van Tinteren; A Keijserd; John Praag; J Knegjens; M Hatton; I van Dam; A van der Leest; B Reymen; J Stigt; K Haslett; D Tripathi; EF Smit; S Senan

doi:10.1016/j.lungcan.2017.03.007

Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial

BJ Slotman
, C Faivre-Finn
, H van Tinteren
, A Keijserd
, John Praag
, J Knegjens
, M Hatton
, I van Dam
, A van der Leest
, B Reymen
, J Stigt
, K Haslett
, D Tripathi
, EF Smit
, S Senan

Radiotherapy

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

93 Citations (Scopus)

137 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	150-153
Number of pages	4
Journal	Lung Cancer
Volume	108
DOIs	https://doi.org/10.1016/j.lungcan.2017.03.007
Publication status	Published - 2017

Research programs

EMC MM-03-32-04

Access to Document

10.1016/j.lungcan.2017.03.007

REPUB_108020_OA.pdfFinal published version, 544 KB

http://hdl.handle.net/1765/108020

Cite this

Slotman, BJ., Faivre-Finn, C., van Tinteren, H., Keijserd, A., Praag, J., Knegjens, J., Hatton, M., van Dam, I., van der Leest, A., Reymen, B., Stigt, J., Haslett, K., Tripathi, D., Smit, EF., & Senan, S. (2017). Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer, 108, 150-153. https://doi.org/10.1016/j.lungcan.2017.03.007

@article{f2d58625f60d4016a8b71799a492a889,

title = "Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial",

author = "BJ Slotman and C Faivre-Finn and \{van Tinteren\}, H and A Keijserd and John Praag and J Knegjens and M Hatton and \{van Dam\}, I and \{van der Leest\}, A and B Reymen and J Stigt and K Haslett and D Tripathi and EF Smit and S Senan",

year = "2017",

doi = "10.1016/j.lungcan.2017.03.007",

language = "Undefined/Unknown",

volume = "108",

pages = "150--153",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Slotman, BJ, Faivre-Finn, C, van Tinteren, H, Keijserd, A, Praag, J, Knegjens, J, Hatton, M, van Dam, I, van der Leest, A, Reymen, B, Stigt, J, Haslett, K, Tripathi, D, Smit, EF & Senan, S 2017, 'Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial', Lung Cancer, vol. 108, pp. 150-153. https://doi.org/10.1016/j.lungcan.2017.03.007

TY - JOUR

T1 - Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial

AU - Slotman, BJ

AU - Faivre-Finn, C

AU - van Tinteren, H

AU - Keijserd, A

AU - Praag, John

AU - Knegjens, J

AU - Hatton, M

AU - van Dam, I

AU - van der Leest, A

AU - Reymen, B

AU - Stigt, J

AU - Haslett, K

AU - Tripathi, D

AU - Smit, EF

AU - Senan, S

PY - 2017

Y1 - 2017

U2 - 10.1016/j.lungcan.2017.03.007

DO - 10.1016/j.lungcan.2017.03.007

M3 - Article

C2 - 28625628

SN - 0169-5002

VL - 108

SP - 150

EP - 153

JO - Lung Cancer

JF - Lung Cancer

ER -